Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

HQPlan-les-Ouates, CH
Size (employees)21 (est)
GeNeuro is headquartered in Plan-les-Ouates, CH
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

GeNeuro Office Locations

GeNeuro has an office in Plan-les-Ouates
Plan-les-Ouates, (HQ)
18 Chemin des Aulx
Show all (1)
Report incorrect company information

GeNeuro Company Life and Culture

Report incorrect company information

GeNeuro Frequently Asked Questions

  • How many employees does GeNeuro have?

    GeNeuro has 21 employees.

  • Who are GeNeuro competitors?

    Competitors of GeNeuro include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is GeNeuro headquarters?

    GeNeuro headquarters is located at 18 Chemin des Aulx, Plan-les-Ouates.

  • Where are GeNeuro offices?

    GeNeuro has an office in Plan-les-Ouates.

  • How many offices does GeNeuro have?

    GeNeuro has 1 office.